Thanks to the discovery of CRISPR-Cas9, gene editing is more accessible than ever before. However, some genetic modifications remain challenging and there are even more factors to consider if your cells are intended for clinical use. By outsourcing your clinical gene editing to REPROCELL, you can achieve the genotype you need before moving on to expensive cell bank manufacturing processes.
Our StemEdit service uses advanced CRISPR-SNIPER* gene editing technology to develop your engineered stem cells. Due to the increased screening specificity of CRISPR-SNIPER, we can successfully achieve complex genetic edits with high accuracy at an early stage. By evaluating the percentage of target cells and determining their transfection efficiency (go/no-go decision point) StemEdit saves time as the SNIPER pre-screen is performed before laborious clone selection.
*SNIPER = Specification of Newly Integrated Position and Exclusion of Random-integration. Note: CRISPR-SNIPER modified cells are developed, manufactured or supplied by GenAhead Bio Inc. under license from ERS Genomics Limited and Broad Institute.